Bullish options flow was detected in BMY stock on December 3, 2019.
Bristol-Myers (BMY) and Acceleron Pharma (XLRN) announced the FDA Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application, or sBLA, for the use of Reblozyl in patients with myelodysplastic syndromes, or MDS, at its meeting on December 18, 2019. Bristol-Myers Squibb is seeking approval of Reblozyl, an erythroid maturation agent representing a new class of therapy, for the treatment of adult patients with very low- to intermediate-risk MDS-associated anemia who have ring sideroblasts and require red blood cell, or RBC, transfusions. Reblozyl is currently being reviewed by the FDA for an indication in patients with MDS, and the agency has set a Prescription Drug User Fee Act, or target action, date of April 4, 2020 for completion of the review. The agency recently granted approval of Reblozyl for the treatment of anemia in adult patients with beta thalassemia who require regular RBC transfusions. Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia. Reblozyl is not approved for the treatment of MDS in any country.